...products. When the company launched in 2015, its lead candidate was an antifungal based on amphotericin B...

...advanced breast cancer and cutaneous T cell lymphoma (CTCL); and Ampholipad, a liposomal formulation of amphotericin B...

...advanced breast cancer and cutaneous T cell lymphoma (CTCL); and Ampholipad, a liposomal formulation of amphotericin B...

...advanced breast cancer and cutaneous T cell lymphoma (CTCL) and Ampholipad, a liposomal formulation of amphotericin B...

...advanced breast cancer and cutaneous T cell lymphoma (CTCL) and Ampholipad, a liposomal formulation of amphotericin B...

...the open-label, U.S. trial include safety and pharmacokinetics. MAT2203 is a lipid-crystal nanoparticle formulation of amphotericin B...
...Bedminster, N.J. Product: MAT2203 (CAmB) Business: Infectious Molecular target: Ergosterol Description: Lipid-crystal nanoparticle formulation of amphotericin B...

...“Other products” includes Letairis ambrisentan for pulmonary arterial hypertension, Ranexa ranolazine for chronic angina, AmBisome amphotericin B...

...of VL. There are two marketed therapies for VL: AmBisome amphotericin b, a unilamellar formulation of amphotericin B...
...other forms of the disease; and iCo Therapeutics Inc. (TSX-V:ICO; OTCQX:ICOTF) has ICo-009 , oral amphotericin B...

...infection while a second agent eliminates the pathogen. Standard of care for Cryptococcal disease is amphotericin B...

...on its development plans for MAT2203 this quarter. MAT2203 is a lipid-crystal nanoparticle formulation of amphotericin B...
...Product: CAmB ( MAT2203 ) Business: Infectious Molecular target: Ergosterol Description: Lipid-crystal nanoparticle formulation of amphotericin B...